Cargando…
Engineering chimeric antigen receptor T cells for solid tumour therapy
Cell‐based immunotherapy, for example, chimeric antigen receptor T (CAR‐T) cell immunotherapy, has revolutionized cancer treatment, particularly for blood cancers. However, factors such as insufficient T cell tracking, tumour heterogeneity, inhibitory tumour microenvironment (TME) and T cell exhaust...
Autores principales: | Liu, Longwei, Qu, Yunjia, Cheng, Leonardo, Yoon, Chi Woo, He, Peixiang, Monther, Abdula, Guo, Tianze, Chittle, Sarah, Wang, Yingxiao |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9736813/ https://www.ncbi.nlm.nih.gov/pubmed/36495108 http://dx.doi.org/10.1002/ctm2.1141 |
Ejemplares similares
-
Engineering enhanced chimeric antigen receptor-T cell therapy for solid tumors
por: Neeser, A., et al.
Publicado: (2023) -
Engineering Chimeric Antigen Receptors
por: Kulemzin, S. V., et al.
Publicado: (2017) -
Chimeric antigen receptor T cells applied to solid tumors
por: Zhou, Zhongguo, et al.
Publicado: (2022) -
Engineering and Design of Chimeric Antigen Receptors
por: Guedan, Sonia, et al.
Publicado: (2018) -
Engineering for Success: Approaches to Improve Chimeric Antigen Receptor T Cell Therapy for Solid Tumors
por: Mata, Melinda, et al.
Publicado: (2019)